

BEST AVAILABLE COPY


RECEIVED
CENTRAL FAX CENTERREMARKS

FEB 22 2007

The Examiner has required a further species election in connection with the pending claims 13-17, 21, 25-29, and 33-37. Specifically, the Examiner has required the identification of a specific compound as an elected species.

Applicants appreciate the courtesy of the telephone interview extended by the Examiner to Applicants' undersigned representative James E. Austin on February 12, 2007. The Examiner requested that a single specific compound is elected by the Applicants, in order to facilitate the searching efforts. During the interview, the Applicants pointed out that election of a single compound in the context of pending claims is contrary to the point of the claimed invention. While this was acknowledged by the Examiner, an election of a single specific compound was considered necessary for search facilitation.

For search purposes only, the Applicants herein elect a single specific compound presented below:



Support for the presented species can be found in Figure 3.

The elected species reads on all of the pending claims 13-17, 21, 25-29, and 33-37.

The Applicants respectfully point out that even if this particular peptoid were used as a transfecting agent, this fact would not teach or suggest screening a diverse library of *unknown* peptoids falling within the scope of formulas I and II of claims 13 and 33.


RECEIVED
CENTRAL FAX CENTER

FEB 22 2007


CONCLUSION

Applicants herein elected a single specific compound, as required by the Examiner. It is understood that the elected species is one illustrative compound in a combinatorial library suitable for identification of transfecting agents. It is also understood that election of a single compound is contrary to the point of the claimed invention, and that a single compound is elected only for search facilitation. Applicants believe that all pending claims are allowable in their present form. Since Applicants have fully and completely responded to the Office Action and have made the required election, a Notice of Allowance is respectfully requested. Please feel free to contact the undersigned at the number provided below if there are any questions, concerns, or remaining issues.

Respectfully submitted,
BEYER WEAVER LLP



James E. Austin
Reg. No. 39,489



Anna Gavrilova
Reg. No. 58,181

CORRESPONDENCE ADDRESS:

Novartis Vaccines and Diagnostics, Inc.
Corporate Intellectual Property
P.O. Box 8097
Emeryville CA 94662-8097